Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complementation Tests00:49

Complementation Tests

A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Null and Alternative Hypotheses01:16

Null and Alternative Hypotheses

The actual hypothesis testing begins by considering two hypotheses. They are termed  the null hypothesis and the alternative hypothesis. These hypotheses contain opposing viewpoints.
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As  a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the population that is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors.

Cancer cell·2026
Same author

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Cell·2026
Same author

Fibroblasts hold the key to TLS formation.

Immunity·2026
Same author

Pan-cancer spatial atlas of tertiary lymphoid structures.

Science (New York, N.Y.)·2026
Same author

Tumour cell-intrinsic complement C1r and C1s regulate cancer cell fitness and shape the immune microenvironment in triple-negative breast cancer.

Cellular and molecular life sciences : CMLS·2026
Same author

Metachronous bilateral renal cancer with immune checkpoint blockade-mediated eradication of bone metastasis: case report.

Frontiers in oncology·2026

Related Experiment Video

Updated: Jun 5, 2026

A Scalable, Cell-Based Method for the Functional Assessment of Ube3a Variants
06:35

A Scalable, Cell-Based Method for the Functional Assessment of Ube3a Variants

Published on: October 10, 2022

Alternative complement pathway assessment in patients with atypical HUS.

Lubka T Roumenina1, Chantal Loirat, Marie-Agnes Dragon-Durey

  • 1Cordeliers Research Center, INSERM UMRS 872, 75006 Paris, France. lubka.roumenina@crc.jussieu.fr

Journal of Immunological Methods
|January 11, 2011
PubMed
Summary

Atypical hemolytic uremic syndrome (aHUS) involves complement system defects, often due to gene mutations. Understanding these genetic causes is crucial for diagnosing and tailoring therapies for aHUS patients.

More Related Videos

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Related Experiment Videos

Last Updated: Jun 5, 2026

A Scalable, Cell-Based Method for the Functional Assessment of Ube3a Variants
06:35

A Scalable, Cell-Based Method for the Functional Assessment of Ube3a Variants

Published on: October 10, 2022

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy.
  • It frequently leads to end-stage renal disease.
  • Defective complement regulation is strongly linked to aHUS pathogenesis.

Purpose of the Study:

  • To review current knowledge on complement activation and regulation in aHUS.
  • To describe genetic analysis and protein quantification methods for aHUS diagnosis.
  • To elucidate mechanisms of aHUS-associated mutations and their impact on protein function.

Main Methods:

  • Review of scientific literature on complement biology and aHUS genetics.
  • Analysis of mutation screening in complement pathway genes (C3, FB, FH, FI, MCP, Thrombomodulin).
  • Discussion of methods for complement protein quantification and antibody detection.

Main Results:

  • Mutations in complement alternative pathway genes are hallmarks of aHUS.
  • Mutations can cause either protein deficiency or dysfunctional protein expression.
  • Endothelial damage is linked to complement dysregulation, with mechanisms under investigation.

Conclusions:

  • Genetic analysis of complement system components is essential for aHUS diagnosis.
  • Understanding mutation mechanisms guides personalized therapeutic strategies for aHUS.
  • Tailoring therapy based on specific genetic defects improves patient outcomes.